Translational Medicine Overview

With specialized pharmacogenomic and pharmacoproteomic biomarker assay capabilities in various therapeutic niches QPS supports development of targeted therapies and personalized medicines
Why should QPS be your first and only choice to conduct all of your translational medicine studies?

Direct Peer-to-Peer Interactions
At QPS we realize that the quality of the biomarker data you receive from us is directly related to the scientific expertise that is available within our laboratories. Each of your biomarker programs will have a dedicated Study Director assigned who has the overall responsibility for the conduct of your study and is your single point of study control to get your science done. The Study Director is available to answer all your questions and provide analysis and interpretation of biomarker data.

Fast Turnaround
The direction taken by your drug discovery and development programs can be substantially influenced by the timely availability of biomarker data. QPS’ state-of-the-art specialized biomarker laboratory services and fast turn around times will help you make your “go/no-go” decisions faster while reducing your total preclinical and clinical study costs. To meet your timeline requirements, we offer for instance custom genotyping services with 48-72 hour data turnaround for patient stratification and inclusion/exclusion decisions to support your global clinical Phase I, II, III, and IV trials.

Global Flexibility
Benefit from QPS’ global resources with the flexibility to transfer methods among any of our four specialized laboratory sites in the USA, Netherlands, Austria and Taiwan. QPS can provide you with a truly “fit-for-purpose” option to support your global clinical studies. QPS is in an excellent position to cater to the growing global biomarker needs by providing access to a large biomarker menu for many types of therapeutic indications.

Customer Focus
QPS focuses on the needs of each client and works to ensure that those needs are met. We strive to ensure optimal communications so you have always complete visibility into your project’s status and can rest assured that your deadlines will be met and your budgets will not be exceeded. At QPS, we measure our success by your success.

Introduction to QPS’ Translational Medicine Services:
With four highly specialized laboratory sites established in the USA, Netherlands, Austria and Taiwan, where QPS’ translational medicine laboratory scientists routinely develop and validate hundreds of new biomarker methods annually, QPS has positioned itself as a true global player in translational medicine laboratory services. As an experienced provider of pharmacogenomics and pharmacoproteomics services for clinical trials, QPS offers you valuable translational solutions to help guide your drug development teams at various levels, including patient stratification, toxicity prediction, evaluation of PK profiles, dose determination, and treatment decisions.
Why should QPS be your first and only choice to conduct all of your translational medicine studies?

**Direct Peer-to-Peer Interactions**
At QPS we realize that the quality of the biomarker data you receive from us is directly related to the scientific expertise that is available within our laboratories. Each of your biomarker programs will have a dedicated Study Director assigned who has the overall responsibility for the conduct of your study and is your single point of study control to get your science done. The Study Director is available to answer all your questions and provide analysis and interpretation of biomarker data.

**Fast Turnaround**
The direction taken by your drug discovery and development programs can be substantially influenced by the timely availability of biomarker data. QPS’ state-of-the-art specialized biomarker laboratory services and fast turn around times will help you make your “go/no-go” decisions faster while reducing your total preclinical and clinical study costs. To meet your timeline requirements, we offer for instance custom genotyping services with 48-72 hour data turnaround for patient stratification and inclusion/exclusion decisions to support your global clinical Phase I, II, III, and IV trials.

**Global Flexibility**
Benefit from QPS’ global resources with the flexibility to transfer methods among any of our four specialized laboratory sites in the USA, Netherlands, Austria and Taiwan. QPS can provide you with a truly “fit-for-purpose” option to support your global clinical studies. QPS is in an excellent position to cater to the growing global biomarker needs by providing access to a large biomarker menu for many types of therapeutic indications.

**Customer Focus**
QPS focuses on the needs of each client and works to ensure that those needs are met. We strive to ensure optimal communications so you have always complete visibility into your project’s status and can rest assured that your deadlines will be met and your budgets will not be exceeded. At QPS, we measure our success by your success.

**Discovery Lab - Innovation**
Our experienced molecular biology and immuno-biomarker scientists can confidently perform the biochemistry of your design, such as a proof-of-concept study originating from your lab or a collaborative effort between you and QPS. We will work to ensure your study is completed to global standards and procedures. Proper optimization and validation of assays are critical steps to your biomarker program. Proper validation includes an assessment of assay sensitivity, specificity and precision. Additional criteria such as accuracy, LLOQ determination, linearity, interferences, normal range evaluation, robustness and other parameters apply for quantitative tests or as appropriate.
**Biomarker Panels:**
- Neurodegeneration Biomarker Panels
- Oncology Biomarker Panels
- Inflammatory Biomarker Panels
- Type 2 Diabetes Biomarker Panels
- Respiratory Biomarker Panels
- For a complete list of our Biomarker Panels please go to: www.qps.com

**Genomic Biomarkers:**
- Nucleic Acids Isolation (DNA & RNA) and Banking
- Genotyping Assays for Drug Metabolizing Enzymes (CYP2B6, CYP3A4, CYP3A5, CYP2C9, CYP2C19, CYP2D6, NAT1, NAT2, UGT1A1, CDA)
- Genotyping Assays for Drug Transporters (ABCG2, SLC01B1)
- Genotyping Assays for Oncology (BRAF, KRAS, PIK3CA)
- Genotyping Assays for Alzheimer’s Disease (ApoE, PPP3R1)
- CpG Methylation Quant
- Multiplexing Genetic Markers (CYP450 TaqMan or Affymetrix DMET genechips)
- Gene Expression Profiling in various matrices (qRT-PCR)

**Proteomic Biomarkers:**
- Immunoassays
- Cell Based Assays
- On-Site Cell Stimulation and Analysis
- Custom Assay Development and Fit-For-Purpose Validation (various matrices)

**Regulatory Status:**
- CLIA certified
- GLP Compliant

---

**Analytical Platform**

<table>
<thead>
<tr>
<th>Analytical Platform</th>
<th>USA</th>
<th>Netherlands</th>
<th>Taiwan</th>
<th>Austria</th>
</tr>
</thead>
<tbody>
<tr>
<td>ELISA/EIA</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>ECL (MSD)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Immulite Clinical Analyzer</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luminex (BioPlex)</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gyrolab</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell-Based Assays</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Flow Cytometry</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPLC</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>LC-MS/MS</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Nephelometry</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICP-MS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Western Blot</td>
<td>x</td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Enzyme Assays</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>RIA/SPA</td>
<td>x</td>
<td></td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>PyroSequencing (genotyping/epigenetics)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TaqMan (genotyping and qRT-PCR)</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RNA/DNA Sample Prep &amp; Analysis</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCR</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>In-Situ Hybridization</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Immunohistochemistry</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Colorimetric Assays</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
</tbody>
</table>
Call to arrange for a tour at one of QPS’ four worldwide Translational Medicine Laboratories today.
Call to arrange for a tour at one of QPS’ four worldwide Translational Medicine Laboratories today:

- **Hyderabad, INDIA**
  - Phase I beds: 92

- **Madrid, SPAIN**
  - Phase I beds: 233

- **New York, FL, USA**
  - Phase I beds: 22

- **QPS|Delaware**

- **QPS|Netherlands**

- **QPS|Austria**

- **QPS|Taiwan**

Company Values: **Integrity** - We make and keep promises and build trust through honesty, proactive communication and reliability.

**Quality** - We bring the highest level of technical expertise and judgement to our work.

**Customer Focus** - We tap our global resources to provide service that is fast, flexible and integrated.

**Commitment** - We work hard to solve problems and deliver results.

**People** - We treat people with dignity, respect and fairness, and embrace our differences.

**Culture** - We are friendly and fun. We provide opportunities to grow, we value loyalty and teamwork, and we recognize and reward performance.

**Time is of the essence in drug development, so contact a member of the QPS Business Development Team today and find out what QPS can do for you.**

**HQ BD Office**
Lily Rosa (USA)

📞 +1 512 350 2827

✉️ info@qps.com